Pharmacoeconomics of treatment with the newer anti-Gram-positive agents

Expert Opinion on Pharmacotherapy
Liangsu Wang, John F Barrett

Abstract

The unmet medical need of emerging resistance among Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae, has driven industry towards the identification and development of novel anti-Gram-positive agents. Among the newer agents are improved quinolones, a lipopeptide, an oxazolidinone and novel glycopeptides. Scientific distinctions between these drugs, which impact on the placement, usage and, ultimately, the pharmacoeconomics of several of these new agents, may lead to further consideration despite poor initial observations of minimal improvement. Key differences in the characteristics of these drugs (i.e., spectrum, activity, resistance emergence, efficacy, target, safety) provide a basis for an emerging pharmacoeconomic-based distinction between these newer anti-Gram-positive agents.

References

Oct 5, 1978·The New England Journal of Medicine·M R JacobsR Austrian
Dec 1, 1994·American Journal of Respiratory and Critical Care Medicine·J RelloR Rodriguez-Roisin
Apr 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P K LindenS Kusne
Dec 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J Romero-VivasJ J Picazo
Feb 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A SorianoE Soriano
May 17, 2001·Antimicrobial Agents and Chemotherapy·A L BarryS D Brown
May 31, 2001·Microbiology and Molecular Biology Reviews : MMBR·I Chopra, M Roberts
Jun 5, 2001·The Journal of Antimicrobial Chemotherapy·O A KhairR Wise
Aug 3, 2001·The Journal of Biological Chemistry·U PatelE V Bobkova
Jan 26, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Clyde ThornsberryJames A Karlowsky
Jul 23, 2002·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael T HalpernJeff Kirsch
Oct 24, 2002·Archives of Internal Medicine·Yehuda CarmeliMatthew Samore
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Jan 8, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David H HowardDeAnn Jones
Jan 17, 2003·Annals of Internal Medicine·Robert C Moellering
Feb 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George M Eliopoulos
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John J EngemannKeith S Kaye
Feb 28, 2003·Expert Opinion on Investigational Drugs·Darren AbbanatKaren Bush
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Grit Ackermann, Arne C Rodloff
Apr 11, 2003·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A Dalhoff, F-J Schmitz
Apr 17, 2003·The Journal of Antimicrobial Chemotherapy·Dilip Nathwani
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseMichael J Rybak
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E Cosgrove, Yehuda Carmeli
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Jared A SilvermanHoward M Shapiro
Mar 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christopher F Carpenter, Henry F Chambers
May 4, 2004·International Journal of Antimicrobial Agents·P BallG Tillotson
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L Paterson
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert D ArbeitUNKNOWN Daptomycin 98-01 and 99-01 Investigators
Jul 10, 2004·American Journal of Respiratory and Critical Care Medicine·Alain CombesUNKNOWN PNEUMA Trial Group
Jul 15, 2004·PharmacoEconomics·Diana De Graeve, Philippe Beutels
Jul 22, 2004·The Annals of Pharmacotherapy·Brian J KoppEdward P Armstrong
Oct 16, 2004·Expert Review of Anti-infective Therapy·Dennis L StevensKarl Madaras-Kelly
Nov 30, 2004·Expert Review of Anti-infective Therapy·David R P Guay
Jan 29, 2005·Drug Discovery Today·Karen M Overbye, John F Barrett
Feb 8, 2005·The Journal of Allergy and Clinical Immunology·Thomas M File

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
L A MandellInfectious Diseases Society of America
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
James A KarlowskyTRUST Surveillance Program
© 2022 Meta ULC. All rights reserved